Icrucumab（Cat No.:I042228）is an investigational monoclonal antibody designed to target and inhibit the protein angiopoietin-2 (Ang-2), a key regulator of angiogenesis (the formation of new blood vessels). Ang-2 plays a critical role in promoting abnormal blood vessel growth in diseases like cancer and diabetic retinopathy. By binding to Ang-2, Icrucumab aims to reduce the destabilization of blood vessels, improve vascular function, and inhibit tumor growth. Clinical trials are exploring Icrucumab’s potential for treating conditions driven by abnormal angiogenesis, including certain cancers and retinal diseases, with a focus on safety and efficacy.
